abstract: 1. Comparative studies of the @entity22878 -directed @entity815 -incorporating activity of cell-free systems derived from @entity35 and @entity1573 livers demonstrated markedly lower activity in the @entity1573 liver system. 2. The @entity1573 liver cell @entity43678 contained the factor(s) responsible for this lower activity. Ribosomes from @entity1573 and @entity35 performed equally well in the presence of @entity35 liver cell @entity43678 . @entity1573 liver cell @entity43678 , when mixed with @entity35 liver cell @entity43678 , caused an inhibition of incorporation of @entity815 into acid-insoluble material. 3. Though ribosomal preparations and cell @entity43678 from both @entity35 and @entity1573 liver degraded @entity22878 to some extent, the @entity1573 liver cell @entity43678 contained the largest amount of activity. 4. @entity35 liver cell @entity43678 inhibited the @entity68235 activities of ribosomal preparations, but no such @entity68235 inhibition could be demonstrated with @entity1573 liver cell @entity43678 .

title: XXXX activity in cell-free amino acid-incorporating systems from @entity1573 liver.

entities_list: @entity1573 :: ('9031', 'Species') :: ['chicken', 'Chicken']

entities_list: @entity22878 :: ('CHEBI:73279', 'Chemical') :: ['polyuridylic acid']

entities_list: @entity815 :: ('CHEBI:28044', 'Chemical') :: ['phenylalanine']

answer: @entity68235 :: (430764(Tax:9031),Gene) :: ['Nuclease']


abstract: 1. The mechanisms of long-term potentiation (LTP) and long-term @entity308 (LTD) induced by brief high frequency stimulation (HFS), paired with a particular pattern and amplitude of depolarisation has been investigated in the medial perforant pathway of the dentate gyrus of the 2- to 3-week-old @entity35 hippocampus in vitro. 2. @entity1024 ( @entity143 ) receptor (NMDAR) activation was measured quantitatively during HFS-induced NMDAR-dependent LTP, LTD and at the LTD--LTP crossover point in order to test the hypothesis that the induction of the particular form of plasticity depends on the intensity of NMDAR activation. 3. The induction of LTD, the LTD--LTP crossover point and LTP was associated with an increasing NMDAR charge transfer. 4. In addition to the NMDAR-dependent LTD, a group I metabotropic @entity2227 receptor (mGluR)-dependent LTD could be induced by high intensity HFS paired with depolarisation under conditions of NMDAR inhibition. 5. The induction of mGluR-dependent LTD requires membrane depolarisation, @entity141 influx via L-type @entity141 channels and a rise in intracellular @entity141 . 6. Quantal analysis involving minimal stimulation demonstrated that the mGluR-dependent LTD induction was associated with a decrease in potency and an increase in failure rate.

title: @entity143 receptor- and metabotropic @entity2227 receptor-dependent synaptic plasticity induced by high frequency stimulation in the XXXX dentate gyrus in vitro.

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity1024 :: ('CHEBI:31882', 'Chemical') :: ['N-Methyl-D-aspartate']

entities_list: @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: OBJECTIVE: This study focused on the efficacy of endoscopic decompression of the foramen guided by endoscopic aware-state @entity158 . BACKGROUND DATA: Endoscopic foraminoplasty consists of undercutting of the facet joint and endoscopic discectomy, mobilization and neurolysis of the exiting and transiting nerves, and ablation of osteophytes. This study sought the outcome of endoscopic foraminoplasty in 250 consecutive @entity1 followed for a minimum of 2 years, reviewed and assessed by an external independent assessor. It was applied to @entity1 with @entity615 and sciatica in multilevel @entity179 and also to those with prior surgery. METHODS: A prospective study of endoscopic laser foraminoplasty was performed on 121 males and 129 females with an average age of 48 years (21-86 years), followed for an average period of 30 months (26-43 months). The average preoperative duration of back, buttock, or leg @entity158 was 6.1 years (5-11 years). A total of 30% had undergone prior open spinal surgery. RESULTS: The cohort integrity at follow up was 97%. Outcome was analyzed using the percentage change in Oswestry Disability Scores and visual analogue @entity158 scores. Clinically relevant change in @entity158 and disability was observed in 73%. Using a percentage change in Oswestry Disability Score of 50 or more to determine good and excellent outcomes, 60% of @entity1 exceeded this score. A total of 95% @entity1 required no further surgical intervention. CONCLUSIONS: Endoscopic laser foraminoplasty provides a minimalist means of exploring the extraforaminal zone, the foramen, the disc, and the epidural space and performing discectomy, lateral recess decompression, osteophytectomy, and neural mobilization. Performed in the aware state, it serves to identify and localize precisely the causal source of @entity158 in multilevel @entity66 , in revision surgery, and in the infirm and elderly without open fusion or decompression.

title: Endoscopic foraminoplasty: a prospective study on 250 consecutive XXXX with independent evaluation.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['disc disease']

entities_list: @entity615 :: ('MESH:D001416', 'Disease') :: ['back pain']

entities_list: @entity179 :: ('MESH:D019636', 'Disease') :: ['degenerative disc disease']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain source definition', 'pain']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: PURPOSE: In a series of @entity14 ( @entity14 ) @entity1 , we evaluated the sensitivities of the individual microsatellites recommended by the National @entity5 Institute (NCI) consensus workshop for detection of @entity2198 ( @entity124 ). On the basis of this evaluation, we developed a three-marker assay that assigns @entity124 ( @entity124 ) in a multiplex polymerase chain reaction. METHODS: Individual marker sensitivity was assessed in 18 @entity14 . Multiplex and NCI assays were then assessed in a series of 120 @entity1 with early-onset @entity694 . RESULTS: The sensitivity of microsatellite markers BAT25, BAT26, D2S123, D5S346, and D17S250 for ASI in @entity14 was 100%, 94%, 72%, 50%, and 50%, respectively. The three most accurate markers were combined and optimized in a multiplex assay that assigned @entity124 whenever at least two of three markers revealed ASI. In early-onset @entity694 , the prevalence of @entity124 determined by the multiplex assay and by the NCI assay was 16% and 23%, respectively. The @entity5 and @entity1 with @entity124 identified by the NCI assay lacked the traits characteristic of @entity124 seen in @entity5 and @entity1 identified by the multiplex assay: retention of heterozygosity (NCI additional 22% v multiplex 84%; P =.003), characteristic @entity5 morphology (0% v 64%; P =.006), and 5-year @entity5 survival rate (44% v 100%; P =.0003). CONCLUSION: The multiplex assay identifies @entity694 with @entity124 by assessing three highly accurate microsatellite markers. This assay identifies a smaller @entity124 cohort with more homogeneous clinical features and is superior as a marker of favorable prognosis. It merits prospective evaluation as a marker of prognosis and as a screening test for @entity14 .

title: Automated, multiplex assay for XXXX in @entity14 .

entities_list: @entity2198 :: ('MESH:D006316', 'Disease') :: ['high-frequency microsatellite instability']

entities_list: @entity124 :: ('MESH:D053842', 'Disease') :: ['MSI-H', 'MSI', 'microsatellite instability']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['additional MSI-H tumors', 'tumor', 'cancer', 'Cancer', 'tumors']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['hereditary nonpolyposis colorectal cancer', 'HNPCC', 'HNPCC tumors', 'HNPCC cancers']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer', 'colon cancers']

answer: @entity2198 :: (MESH:D006316,Disease) :: ['high-frequency microsatellite instability']


abstract: OBJECTIVE: The statement that @entity1653 are @entity5 has to be seriously questioned from a surgical standpoint. The purpose of this study was 1) to analyze the operative reports of a personal series of @entity1653 to evaluate the percentages of the @entity5 that could be dissected by passing in the extrapial plane (i.e., "cleavable") and of those in which the dissection had to be subpial (i.e., "noncleavable") and 2) to see whether preoperative angiography could help in predicting cleavability. METHODS: The series includes 150 consecutive @entity1 with @entity1653 diagnosed with computed tomographic scans and explored preoperatively by selective external/internal carotid angiography, operated on using microsurgical techniques, and followed for more than 4 years. RESULTS: Dissection between @entity5 and underlying cortex could be achieved in the extrapial plane predominantly (i.e., on more than two-thirds of the interface) in only 54.6% of @entity1 . On angiography, the pial-cortical arterial supply participated in at least equal part with the meningeal-dural arterial supply in vascularization of the @entity5 in 59.4% of @entity1 . In this group, dissection could pass through the extrapial plane in only 34.8% of @entity1 . Conversely, when meningeal-dural arterial supply was predominant on angiography, which occurred in 40.6% of @entity1 , dissection could be achieved in the extrapial plane in 83.6% of @entity1 . This difference is statistically significant (P < 0.001). CONCLUSION: Participation of pia mater in the vascular supply of @entity1653 , and consequently, difficulty of dissection, can be predicted preoperatively on angiography. Knowledge of the arterial supply of the @entity5 before surgery is an important aid to the surgeon in preparing for and performing the operation.

title: Most @entity1653 are not XXXX : anatomic-surgical evidence and angiographic predictibility.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cleavable tumors', 'tumors']

entities_list: @entity1653 :: ('MESH:D008579', 'Disease') :: ['intracranial meningiomas', 'meningiomas']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cleavable tumors']


abstract: BACKGROUND: Since most studies concerning the frequency of @entity73 of @entity303 are based on samples of @entity146 services, the results of these studies may be influenced by their selection procedure. For this reason, we investigated the frequency of non-cognitive @entity303 symptoms based on an epidemiological nursing home study. METHODS: The sample consisted of 249 nursing home residents in Austria who were interviewed with the Clinical Interview Schedule within 2 weeks after admission (T1) and again 6 months later (T2). For the analyses of the @entity73 among the demented, only manifest clinical abnormalities observed during the interview were included. Further, mobility and impaired self-care were assessed. RESULTS: At admission, @entity303 was found in 63.9% of the sample. At T1, 38%, and at T2, 36.1% of the demented suffered from any @entity73 . Flattened or incongruous affect, suspiciousness or @entity146 , and @entity148 were found most frequently. Multiple regression analyses showed that @entity73 increase the risk for impaired self-care. DISCUSSION: Despite the fact that the frequency of several @entity73 found in our survey is lower than reported from studies based on @entity146 samples, a high proportion of the demented in nursing homes suffer from such symptoms. Non-cognitive symptoms of @entity303 increase the risk for an impaired self-care, which supports the assumption that they raise the costs of caring.

title: Non-cognitive symptoms of XXXX in nursing homes: frequency, course and consequences.

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['non-cognitive symptoms']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric', 'aggressiveness']

answer: @entity303 :: (MESH:D003704,Disease) :: ['dementia']


abstract: @entity1 intraepithelial lymphocytes are T cells primarily of the @entity405 + phenotype located between intestinal epithelial cells. The cytotoxic and suppressor activities of these lymphocytes are largely unexplored. The spontaneous cytotoxic activity of these cells is evaluated in this study. Jejunal intraepithelial lymphocytes spontaneously lysed a variety of epithelial cell @entity5 lines ( @entity788 and @entity150 ) but not the highly natural killer-sensitive K-562 cells. Cold target inhibition studies showed that these lymphocytes preferentially bind the DLD-1 @entity694 cells rather than the K-562 cells. Pretreatment of the effector cells with @entity379 did not change their cytotoxic activity. The cytotoxic cells are T lymphocytes (expressing @entity3138 , CD3, and @entity405 ). In contrast, the spontaneous cytotoxic activity of peripheral blood lymphocytes is directed against both epithelial cell targets and K-562 cells, is enhanced by @entity379 , and is effected by natural killer cells (expressing @entity3138 , @entity4071 , and NKH1). Thus, the spontaneous @entity137 of intraepithelial lymphocytes differs from that of peripheral blood lymphocytes in their target cell restriction, lack of response to interferon gamma, and effector cell phenotype. Lymphocytes in the intestinal epithelium may have a novel and important role in recognizing and destroying transformed epithelial cells and @entity694 .

title: Spontaneous @entity137 of @entity1 intraepithelial lymphocytes against epithelial cell XXXX .

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['colonic and pancreatic adenocarcinomas']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder epidermoid carcinoma']

entities_list: @entity379 :: ('3458', 'Gene') :: ['interferon-gamma']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancers', 'colonic adenocarcinoma']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumors']


abstract: UNASSIGNED: High systolic blood pressure (SBP) variability has been associated with higher risk for target-organ damage. In a cross-sectional study done in a tertiary outpatient @entity101 clinic, we compared short-term SBP variability among controlled and uncontrolled @entity101 @entity1 and evaluated the association between higher levels of SBP variability and diastolic function and @entity4346 ( @entity4346 ). @entity1 were evaluated by 24-h ambulatory blood pressure monitoring and transthoracic Doppler echocardiogram. Blood pressure (BP) variability was evaluated by the time-rate index and high variability corresponded to index values in the top quartile of distribution. Echocardiographic parameters were compared in @entity1 with and without higher BP variability within controlled and uncontrolled office BP (   140/90   mm   Hg). The analyses included 447 @entity1 with 58  12 years of age, 67% were @entity1 , 68% white, 43% current or previous smokers and 32% with @entity6 . Among the whole sample, 137 @entity1 had controlled and 310 uncontrolled BP. The 75th percentile cutoff points for the time-rate index were 0.502   mm   Hg   min(-1) and 0.576   mm   Hg   min(-1) for @entity1 with controlled and uncontrolled BP, respectively. After adjustment for confounders, the time-rate index did not differ between controlled and uncontrolled @entity1 . BP variability was not associated with @entity4346 or diastolic function in controlled and uncontrolled BP after adjustment for 24-h SBP and age. @entity1 with controlled and uncontrolled BP had similar SBP variability assessed by time-rate index, which was not associated with @entity4346 or diastolic function. These findings should be confirmed in studies with larger sample size.Journal of @entity1 @entity101 advance online publication, 15 October 2015; doi:10.1038/jhh.2015.106.

title: Blood pressure variability in controlled and uncontrolled blood pressure and its association with XXXX and diastolic function.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'Patients', 'patients', 'Human']

entities_list: @entity4346 :: ('MESH:D017379', 'Disease') :: ['LVH', 'left ventricular hypertrophy']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive', 'Hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']

answer: @entity4346 :: (MESH:D017379,Disease) :: ['left ventricular hypertrophy']


abstract: Hepatic lipid synthesis is known to be regulated by food consumption. In rodents fasting decreases the synthesis of @entity165 as well as @entity1718 . Refeeding a high @entity1735 /low fat diet enhances @entity844 synthesis by 5- to 20-fold above the fed state, whereas @entity165 synthesis returns only to the prefasted level. @entity5068 regulatory element binding proteins (SREBPs) are transcription factors that regulate genes involved in @entity165 and @entity844 synthesis. Here, we show that fasting markedly reduces the amounts of @entity69534 in @entity19 liver nuclei, with corresponding decreases in the mRNAs for SREBP-activated target genes. Refeeding a high @entity1735 /low fat diet resulted in a 4- to 5-fold increase of nuclear @entity4062 above nonfasted levels, whereas nuclear @entity59998 protein returned only to the nonfasted level. The hepatic mRNAs for @entity844 biosynthetic enzymes increased 5- to 10-fold above nonfasted levels, a pattern that paralleled the changes in nuclear @entity4062 . The hepatic mRNAs for enzymes involved in @entity165 synthesis returned to the nonfasted level, closely following the pattern of nuclear @entity59998 regulation. @entity19 that overproduce nuclear @entity4062 failed to show the normal decrease in hepatic mRNA levels for @entity165 and @entity844 synthetic enzymes upon fasting. We conclude that SREBPs are regulated by food consumption in the @entity19 liver and that the decline in nuclear @entity4062 upon fasting may explain in part the decrease in mRNAs encoding enzymes of the @entity844 biosynthetic pathway.

title: Regulation of @entity5068 regulatory element binding proteins in livers of fasted and refed XXXX .

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity19 :: ('10090', 'Species') :: ['Transgenic mice', 'mouse']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity19 :: (10090,Species) :: ['mice']


abstract: OBJECTIVES: This study reports survival, functional status, the change in post-operative left ventricular dimensions and function after'undersized mitral annuloplasty' in @entity1 with non-ischaemic @entity384 and secondary @entity339 . @entity1 AND METHODS: Between 2003 and 2009 10 @entity1 (mean age 61.5 +/- 14 years) with non-ischaemic, @entity384 with left ventricular ejection fraction (LV EF) <40% (mean +/- SD, 30.7 +/- 5.27) underwent isolated mitral repair and annuloplasty. All @entity1 were receiving maximal drug therapy. Preoperatively 1 @entity1 (10%) was functioning in New York Heart Association (NYHA) class II, 8 @entity1 (80%) in class III and 1 @entity1 (10%) in class IV. Transthoracic echocardiography was performed immediately before surgery and one year after surgery to assess valvular and ventricular function. For statistical analysis we have used paired t-tests and Wilcoxon's rank test. RESULTS: There were no hospital deaths. Duration of intubation and ICU stay was 1.8 +/- 1.3 and 3.8 +/- 1.8 days, respectively. Functional class after one year was significantly better than the preoperative value (from 3.00 +/- 0.47 to 1.40 +/- 0.52, P<0.001). One year post-operative data showed significant improvement of LV EF (from 30.70 +/- 5.27 to 46.60 +/- 14.47%) and a decrease of the left ventricular diastolic dimension (LVDd) (from 59.30 +/- 5.62 to 50.70 +/- 6.04 mm). CONCLUSION: Isolated undersized mitral annuloplasty in @entity1 with non-ischaemic @entity384 with associated @entity339 , is a safe method with the potential of improving functional class, LV EF, and LVDd after one year.

title: Mitral annuloplasty for @entity384 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['non-valvular dilated cardiomyopathy']

entities_list: @entity339 :: ('MESH:D008944', 'Disease') :: ['mitral regurgitation']

answer: @entity339 :: (MESH:D008944,Disease) :: ['mitral regurgitation']


abstract: Seventeen examples of a variant of @entity513 in situ (DCIS) composed exclusively or predominantly of spindle cells arranged in fascicles, whorls, and solid sheets are described. The fascicular arrangement of the spindle cells simulates the "streaming" phenomenon associated with @entity2543 (IDH). This process also resembles the myoid, solid form of intraductal myoepithelial proliferation. The @entity1 ranged in age from 38 years to 79 years with a mean age of 59.3 years. Five @entity1 presented with a palpable mass. The remaining @entity5 were discovered using mammography. The radiological appearances of the lesions raised concern for @entity189 , but there were no distinctive mammographic findings to suggest an unusual variant of DCIS. Cytological preparations were suspicious for @entity5 in two @entity1 and were reported as malignant in another case. Sixteen @entity1 were treated with wide local excision, and one @entity1 had a partial mastectomy. The @entity5 measured from 3 mm to 15 mm (mean 8.65 mm). In three cases, minute foci of stromal invasion were associated with the spindle cell DCIS. In another specimen, a 2.7-cm @entity513 of no special type was identified in an area away from the foci of the spindle cell DCIS. None of the @entity1 has experienced recurrence or @entity3 during the relatively short mean follow-up period of 16.2 months (range 4-77 months). Spindle cell DCIS is distinguished from the streaming pattern of ordinary IDH by its solid growth pattern, lack of secondary spaces or peripheral fenestrations, uniformity of appearance and distribution of nuclei, cytological atypia in the range of low to intermediate-grade DCIS, and negative immunoreaction with CK-34betaE12 (HMW-CK903). When fenestrations are present, they are evident in areas of cribriform DCIS that merge with the solid, spindle cell areas in hybrid ducts harboring both patterns. This admixture, with conventional cribriform DCIS, and the association with foci of @entity513 in some cases further help recognition and confirmation of this lesion as in situ @entity189 . When there is no transition from the spindle cells to recognizable cribriform DCIS, distinction from @entity1373 (myoepitheliosis) requires immunostains for actin and @entity4483 protein. Recognition of this pattern of DCIS is important in order to avoid its frequent misclassification as a benign lesion.

title: @entity513 in situ. An unusual variant of XXXX that simulates @entity1373 or a myoepithelial proliferation.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'woman', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy', 'tumors']

entities_list: @entity1373 :: ('MESH:D006965', 'Disease') :: ['intraductal myoepithelial hyperplasia']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

entities_list: @entity513 :: ('MESH:D044584', 'Disease') :: ['ductal carcinoma', 'invasive ductal carcinoma']

entities_list: @entity2543 :: ('MESH:D017573', 'Disease') :: ['ordinary intraductal epithelial hyperplasia']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity5 :: (MESH:D009369,Disease) :: ['ductal intra-epithelial neoplasia']


abstract: We assessed effects of passive sensitization on @entity1 bronchial smooth muscle (BSM) response to mechanical stretching in vitro. Bronchial rings were sham (control) or passively sensitized overnight by using sera from donors demonstrating sensitivity to @entity8786 and having immunoglobulin E ( @entity9416 ) concentrations of 2,600 +/- 200 U/ml. Tissues were fixed isometrically to force transducers to measure responses to electrical field stimulation (EFS) and quick stretch (QS). The myogenic response to QS was normalized to the maximal response to EFS (%EFS). The myogenic response of sensitized BSM was 47.9 +/- 10.9 %EFS to a QS of approximately 6.5% optimal length (Lo); sham-sensitized tissues had a myogenic response of 13.5 +/- 6.4 %EFS (P = 0.012 vs. passively sensitized). A QS of approximately 13% Lo in sensitized BSM caused a response of 82.8 +/- 20.9 %EFS; sham-sensitized tissues developed a response of 38.2 +/- 17.3 %EFS (P = 0.004). BSM incubated with serum from nonallergic donors did not demonstrate increased QS response (4.6 +/- 1.4 %EFS, P = not significant vs. tissue exposed to @entity1097 ). However, tissues incubated in sera from nonatopic donors supplemented with hapten-specific chimeric @entity9416 (JW8) demonstrated augmented myogenic response to QS of approximately 6.5% Lo (21.9 +/- 6.2 %EFS, P = 0. 027 vs. nonatopic sera alone). We demonstrate that passive sensitization of @entity1 BSM preparations causes induction and augmentation of myogenic contractions to QS; this hyperresponsiveness corresponds to the @entity9416 concentration in sensitizing sera.

title: Passive sensitization of XXXX airways induces myogenic contractile responses in vitro.

entities_list: @entity8786 :: ('6954', 'Species') :: ['Dermatophagoides farinae']

entities_list: @entity1097 :: ('MESH:C566404', 'Disease') :: ['atopic sera']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVE: To investigate the neuromuscular activity of the gastrointestinal tract by antroduodenal manometry in @entity1 with @entity46 documented by laparoscopy, to assess the effects of diet and drug therapy on symptoms, and to assess the @entity6124 that is commonly associated with these @entity66 . DESIGN: Prospective, open-label study. SETTING: A clinical center for the care of @entity1 's health. @entity1 (S): Fifty @entity1 with @entity46 documented by laparoscopy and @entity344 characterized by chronic @entity490 , @entity390 , @entity391 , early satiety, bloating and distention, and altered bowel habits. INTERVENTION(S): Motility of the gastrointestinal tract was recorded and @entity6124 was assessed. Treatment consisted of dietary changes, including reduction of glycemic @entity3363 , balancing with omega 9 oils, elimination of foods with @entity5834 and @entity6114 , and addition of @entity9539 , as well as drug therapy with @entity2053 (0.25 mg 3 times per day). RESULT(S): All 50 @entity1 showed a characteristic motility change (ampulla of @entity2473 , a @entity410 equivalent of the enteric nervous system). Forty of the @entity1 showed @entity6124 . There was a significant reduction in the total symptom score after 8 weeks of treatment. CONCLUSION(S): This study suggests that @entity46 and @entity344 are a result of the dysfunction of hollow organs. Correction of the biochemical imbalance of the eicosanoid system and the hypersecretion of insulin that results from excessive intake of glycemic @entity3363 and lack of essential @entity1718 significantly decreases symptoms in @entity1 with @entity46 and associated @entity4094 of the gastrointestinal tract.

title: Relation of XXXX of the gastrointestinal tract: new insights.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'PATIENT']

entities_list: @entity4094 :: ('MESH:D009468', 'Disease') :: ['neuromuscular disease']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['nerve diseases']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity5834 :: ('MESH:D002110', 'Chemical') :: ['caffeine']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal tract symptoms']

entities_list: @entity46 :: ('MESH:D004715', 'Disease') :: ['endometriosis']

entities_list: @entity2473 :: ('MESH:D013035', 'Disease') :: ['Vater-duodenal wall spasm']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity9539 :: ('MESH:D015525', 'Chemical') :: ['omega 3 fatty acids']

entities_list: @entity6124 :: ('MESH:D001765', 'Disease') :: ['bacterial overgrowth']

entities_list: @entity2053 :: ('MESH:D002998', 'Chemical') :: ['clonazepam']

entities_list: @entity3363 :: ('MESH:D002241', 'Chemical') :: ['carbohydrates']

entities_list: @entity6114 :: ('MESH:D014439', 'Chemical') :: ['tyramine']

answer: @entity4094 :: (MESH:D009468,Disease) :: ['endometriosis and neuromuscular disease']


abstract: BACKGROUND: The majority of @entity1 with @entity2971 ( @entity2971 ) are curable with standard therapy. The molecular differences between curable and incurable disease are unknown. We have studied the expression of @entity2467 and the @entity470 ( @entity470 ) to determine their incidence in @entity66 . @entity1 AND METHODS: We retrospectively analyzed 23 @entity1 with chemorefractory non-seminomatous @entity2971 (15 late relapse and eight transformed @entity44 ). None of these 23 @entity1 were cured by their initial chemotherapy and/or surgery. Immunohistochemical analysis of @entity2467 and @entity470 was performed on the most recently available specimen from a metastatic site. PCR amplimers of @entity2467 exon 17 were screened for mutations by a combination of denaturing high-performance liquid chromatography and direct sequencing. RESULTS: @entity2467 was expressed (>/=10% of the @entity5 displaying membranous or cytoplasmic staining) in 11 of 23 @entity1777 @entity1 [48%; 95% confidence interval (CI) 26% to 68%]. There were no activating @entity2467 mutations in the phosphoryltransferase domain (exon 17) in 21 @entity1 analyzed. @entity470 was expressed (1+ to 3+) in 15 of 23 @entity1777 @entity1 (65%; 95% CI 41% to 82%). CONCLUSIONS: @entity2467 and @entity470 are expressed in a significant proportion of refractory @entity2971 . The significance of these findings will be determined by ongoing clinical trials.

title: Expression of @entity2467 and XXXX in chemotherapy refractory non-seminomatous @entity2971 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['chemorefractory disease']

entities_list: @entity2971 :: ('MESH:D009373', 'Disease') :: ['GCTs', 'germ-cell tumors']

entities_list: @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor']

entities_list: @entity44 :: ('MESH:D013724', 'Disease') :: ['teratomas']

answer: @entity470 :: (1956,Gene) :: ['epidermal growth factor receptor']


abstract: STUDY OBJECTIVE: To determine whether changes in serum @entity413 , serum @entity972 , and plasma @entity2690 levels are correlated in a cohort of @entity101 @entity1 . DESIGN: Prespecified subgroup analysis of results from a prospective, multicenter, randomized, open-label, parallel-group study. Setting. Primary care clinics at three tertiary care medical centers. @entity1 : Community-based ambulatory population of 202 @entity1 (age range 17-65 yrs) with a new diagnosis of @entity101 , untreated @entity101 , or known @entity101 , who were previously treated with fewer than three antihypertensive drugs and had no evidence of @entity65 or @entity6 . Intervention. Monotherapy with oral @entity918 12.5 or 25 mg/day for 9 weeks. MEASUREMENTS AND MAIN RESULTS: Fasting serum @entity413 , serum @entity972 , and plasma @entity2690 levels were obtained at baseline (before @entity918 therapy was started) and after 9 weeks of therapy. Significant elevations were noted in fasting serum @entity413 (mean +/- SD 3.42 +/- 10.38 mg/dl, p<0.0001) and plasma @entity2690 (2.35 +/- 9.47 microU/ml, p<0.0001) levels, and a significant reduction in serum @entity972 level (0.30 +/- 0.44 mEq/L, p<0.0001) was noted. No significant correlation was observed between changes in fasting serum @entity413 and @entity972 levels (r = 0.022, 95% confidence interval (CI) -0.120-0.164, p=0.757) or between changes in serum @entity972 and plasma @entity2690 levels (r = -0.112, 95% CI -0.256-0.037, p=0.140). Changes in serum @entity413 levels did not differ significantly between patients maintaining serum @entity972 levels of 4.0 mEq/L or greater and those with levels below 4.0 mEq/L. CONCLUSION: Changes in serum @entity972 and serum @entity413 levels were not correlated in individuals receiving @entity918 monotherapy; thus maintenance of normal @entity972 levels may not attenuate the risk of @entity6662 diuretic-induced @entity4854 .

title: Lack of correlation between @entity6662 -induced XXXX and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']

entities_list: @entity918 :: ('MESH:D006852', 'Chemical') :: ['hydrochlorothiazide']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

entities_list: @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity4854 :: (MESH:D006943,Disease) :: ['hyperglycemia']


abstract: Because @entity528 is triggered by several parallel mechanisms, a combination of drugs active against individual death-promoting mechanisms may have synergistic effects. @entity10025 is a noncompetitive @entity143 antagonist with anti-inflammatory effects and @entity11933 is a @entity29254 antioxidant. Therefore, we explored whether their combined use results in smaller @entity1188 volumes as compared with their individual administration. @entity35 underwent @entity2500 ( @entity2500 ) and were given vehicle, @entity10025 alone, @entity11933 alone, or a combination of @entity10025 and @entity11933 (n = 13 per group) 1 h later. Five animals in each group were evaluated with a motor rating scale 24 h after @entity2500 and the @entity1188 volumes were then measured. The remaining animals were examined with motor and behavioral scales up to 30 days after @entity2500 and their @entity1188 volumes were then determined. Motor disability and water maze latencies at all time points examined and @entity1188 volumes at days 1 and 30 were significantly reduced in all active treatment groups when compared with vehicle. However, no significant differences were observed between the active treatment groups. In conclusions, combination therapy with @entity10025 and @entity11933 does not appear to have additional neuroprotective effects compared to those conferred by each agent alone even when administered at optimal timing and dosing. Therefore, a ceiling neuroprotective effect that is impossible to overcome may exist.

title: Combination of @entity10025 and XXXX in focal cerebral ischemia: is there a ceiling effect?

entities_list: @entity10025 :: ('MESH:C062018', 'Chemical') :: ['dexanabinol', 'Dexanabinol']

entities_list: @entity2500 :: ('MESH:D020244', 'Disease') :: ['PMCAO', 'permanent middle cerebral artery occlusion']

entities_list: @entity29254 :: ('CHEBI:29767', 'Chemical') :: ['nitroxide']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['ischemic neuronal death']

answer: @entity11933 :: (MESH:C001803,Chemical) :: ['tempol']


abstract: The feasibility of medical control of and prevention of uterine @entity548 secondary to @entity1503 by the induction of prolonged @entity2588 with @entity230 was investigated. 29 @entity1 were treated during a 30-month period. Mean age was 25.7 years and mean parity was 1.8. @entity697 and @entity3039 were the most frequently primary diseases. @entity102 , @entity740 , and @entity2150 were also diagnosed. In 23 @entity1 @entity931 had an unfavorable effect on the primary illness and in 14 it was present when treatment began. All platelet counts were very low. 3 drug regimens were used: 1) @entity8472 + @entity8473 , 2) @entity11796 ( @entity12135 ), and 3) @entity12135 + conjugated @entity172 . Significant @entity1867 occurred in 7 @entity1 (24%) and was not related to the degree of @entity882 . Average length of treatment was 15.3 weeks. During the study 18 @entity1 died of their @entity66 . Treatment was discontinued in 7 because of improvement in the @entity66 . In 4 treatment is being continued. As @entity12135 is released slowly, in 10 urgent cases iv conjugated @entity172 were given until @entity548 was controlled or @entity11796 was given orally for a few days. Results show the feasibility of this method of producing therapeutic @entity2588 in the management of a variety of @entity1503 . Fluid retention was more frequent with high @entity172 dosage.

title: Therapeutic @entity2588 in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogens', 'estrogen']

entities_list: @entity697 :: ('MESH:D000208', 'Disease') :: ['Acute lukemia']

entities_list: @entity11796 :: ('MESH:D017258', 'Chemical') :: ['medroxyprogesterone acetate', 'depomedroxyprogesterone acetate']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['primary disease']

entities_list: @entity2150 :: ('MESH:D000741', 'Disease') :: ['aplastic anemia']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['Chronic lukemia']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['chronic renal disease']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematologic disease', 'hematologic diseases']

entities_list: @entity8473 :: ('MESH:D008656', 'Chemical') :: ['mestranol']

entities_list: @entity8472 :: ('MESH:D009641', 'Chemical') :: ['norethynodrel']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

entities_list: @entity3039 :: ('MESH:D016553', 'Disease') :: ['immune thrombocytopenic purpura']

entities_list: @entity931 :: ('MESH:D008595', 'Disease') :: ['menorrhagia']

entities_list: @entity2588 :: ('MESH:D000568', 'Disease') :: ['amenorrhea']

entities_list: @entity1867 :: ('MESH:D008796', 'Disease') :: ['breakthrough bleeding']

answer: @entity1503 :: (MESH:D006402,Disease) :: ['hematologic disorders']


abstract: Alternative RNA splicing can be regulated in a highly cell- and tissue-specific or developmentally specific manner. In neurons, the functions of many gene products, such as those of @entity26303 genes are regulated by alternative splicing. In this paper the mechanism of neural-specific RNA splicing is investigated using @entity26303 genes as models. First, we confirm the splicing patterns of @entity26303 transcripts during neural differentiation of P19 @entity189 ( @entity189 ) cells. The full-length form of @entity26304 was expressed in the neuronal state. In contrast, both the full-length and truncated forms of @entity26303 C were expressed constitutively in all differentiation states. However, two alternatively spliced forms with either 42- or 117- @entity377 insertions in the @entity669 kinase domain were detected only in the neuronal state. Thus, the expression of functional @entity26304 and C was found to be regulated by alternative splicing during neural differentiation. To examine the molecular basis of neural-specific splicing, and how splicing regulation is modulated in different neurons. The expression of a number of general splicing factors was studied. The mRNA levels of the splicing factors @entity29174 , U2AF SF3a, @entity55672 and @entity65202 was found to decrease rapidly during differentiation. In contrast, Nova, an RNA-binding protein was expressed in the neuronal state. We also found that the levels of two SR proteins, members of a family of splicing factors, increased in the neuronal state. These results suggest that the stoichiometric balance among some splicing factors, including SR proteins, may be associated with the alternative splicing of @entity26303 transcripts during differentiation.

title: Changes in pre-mRNA splicing factors during neural differentiation in P19 XXXX cells.

entities_list: @entity377 :: ('CHEBI:36976', 'Chemical') :: ['nucleotide']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['embryonal carcinoma', 'EC']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity189 :: (MESH:D002277,Disease) :: ['embryonal carcinoma']


abstract: OBJECTIVE: Tubal lesions detected in specimen of risk reducing salpingo oophorectomy (RRSO) for mutation @entity6069 seems to play a @entity43 . The main objective of this study is to evaluate the prevalence of occult @entity5 , of @entity189 ( @entity189 ), and signature @entity876 in a cohort of @entity1 who underwent a risk reducing salpingo oophorectomy. METHODS: From January  2010 to January  2014 unicentric, retrospective study on a consecutive cases cohort of RRSO for @entity1 with a high risk of @entity43 (mutation @entity6069 or family history). Pathological specimen should be analysed according to the SEE-FIM protocol. RESULTS: Ninety-three RRSO were recorded. Among them, 44% of the @entity1 had the germ line mutation @entity5345 , 30.1% BRAC2 and 18.2% had no identified mutation. In all, 33.3% of the RRSO reveal a signature @entity876 , in the fimbria for 93.9%, 7.9% of them were bilateral. 1,1    (n=1) of the @entity1 presented a unilateral @entity189 . We obtained 4.3% of occult neplasia: 3  ovarian high-grade serous @entity189 and 1  tubal high-grade @entity189 . Only the tubal @entity189 coexists with @entity189 . CONCLUSION: 5,4% of the @entity1 who underwent RRSO had a diagnostic of occult @entity5 . One percent of the @entity1 had an isolated @entity189 . These results agree with recent data of the literature. Extensive examination of the Fallopian tube opens up a new way to understand @entity43 .

title: [Early epithelial lesions in prophylactic annexectomies in XXXX at high risk of @entity43 : Report of a series of 93  cases].

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian neoplasia', 'ovarian carcinogenesis', 'role in ovarian carcinogenesis']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['neoplasia']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['serous carcinoma', 'carcinomas', 'Serous Tubal Intraepithelial Carcinoma', 'carcinoma', 'STIC']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: The safety and effectiveness of @entity4967 plus @entity798 was evaluated in an open study of 43 @entity1 with community-acquired lower @entity1729 . The mean age of the 28 @entity1 in whom bacteriologic evaluations were possible was 55 years; at least two thirds of the @entity1 had a history of @entity988 or @entity1030 . A pathogen was isolated from sputum samples in 23 @entity1 ; five of these 23 also had documented @entity2259 . There were five additional cases of @entity2259 associated with clinical signs and symptoms of @entity55 but with no organisms isolated from sputum cultures. Thirty-five pathogens were isolated from the 33 evaluable @entity281 sites, primarily @entity328 and @entity6932 . @entity2260 was the causative organism in all 10 cases of @entity2259 . @entity4967 plus @entity798 (3 g of @entity4967 and 100 mg of @entity798 ) was administered intravenously for a mean of six days. All 35 organisms isolated before treatment were eradicated. In one @entity1 a superinfection with @entity796 developed after treatment with @entity4967 plus @entity798 . A clinical evaluation was possible for 32 of the 33 @entity281 sites; clinical cure was achieved at 31 sites and improvement was seen at the other site. All 43 @entity1 were monitored for adverse reactions by both clinical observation and laboratory tests. In one @entity1 , reversible @entity882 developed that required discontinuation of @entity4967 plus @entity798 . In another @entity1 , there was a slight decrease in the @entity972 level during therapy. No systemic adverse reactions occurred, nor was there any instance of local effects associated with the intravenous infusion of the drug.

title: Safety and effectiveness of @entity4967 plus XXXX in treatment of lower @entity1729 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium']

entities_list: @entity796 :: ('287', 'Species') :: ['Pseudomonas aeruginosa']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity988 :: ('MESH:D000437', 'Disease') :: ['alcoholism']

entities_list: @entity798 :: ('MESH:D019818', 'Chemical') :: ['clavulanic acid', 'clavulanate potassium']

entities_list: @entity6932 :: ('MESH:D008583', 'Disease') :: ['Hemophilus influenzae']

entities_list: @entity4967 :: ('MESH:D013982', 'Chemical') :: ['ticarcillin', 'Ticarcillin']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity1729 :: ('MESH:D012141', 'Disease') :: ['respiratory tract infections']

entities_list: @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic obstructive pulmonary disease']

entities_list: @entity328 :: ('1313', 'Species') :: ['Streptococcus pneumoniae']

entities_list: @entity2259 :: ('MESH:D016470', 'Disease') :: ['bacteremia']

answer: @entity798 :: (MESH:D019818,Chemical) :: ['clavulanate potassium']


abstract: BACKGROUND: @entity1 with moderate-to-severe @entity483 ( @entity483 ) often require photo- or systemic immunomodulatory therapies to induce disease remission and maintain long-term control. The current evidence to guide clinical management is small, despite the frequent and often off-label use of these treatments. Registries of @entity1 on photo- and systemic immunomodulatory therapies could fill this gap, and the collection of a core set concerning these therapies in @entity483 will allow direct comparisons across registries as well as data sharing and pooling. Using an eDelphi approach, the international TREatment of @entity483 (TREAT) Registry Taskforce aims to seek consensus between key stakeholders internationally on a core set of domains and domain items for @entity483 @entity1 registries with a research focus that collect data of @entity1 and adults on photo- and systemic immunomodulatory therapies. METHODS/DESIGN: @entity1 from six stakeholder groups will be invited: doctors, nurses, non-clinical researchers, @entity1 , as well as industry and regulatory body representatives. The eDelphi will comprise three sequential online rounds, requesting @entity1 to rate the importance of each proposed domain and domain items. @entity1 will be able to add domains and domain items to the proposed list in round 1. A final consensus meeting will be held with representatives of each stakeholder group. DISCUSSION: Identifying a uniform core set of domains and domain items to be captured by @entity483 @entity1 registries will increase the utility of individual registries, and provide greater insight into the effectiveness, safety and cost-effectiveness of photo- and systemic immunomodulatory therapies to guide clinical management across dermatology centres and country borders. TRIAL REGISTRATION: Not applicable. This eDelphi study was registered in the Core Outcome Measures for Effectiveness Trials (COMET) database.

title: TREatment of XXXX (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national @entity483 registries.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'children', 'Patients', 'patients', 'patient', 'Participants']

entities_list: @entity483 :: ('MESH:D003876', 'Disease') :: ['AE', 'atopic eczema', 'ATopic eczema']

answer: @entity483 :: (MESH:D003876,Disease) :: ['ATopic eczema']


abstract: We examined whether plasma @entity2002 levels and the beta- @entity2002 gene G(-455)-->A polymorphism were related to microvascular or @entity66 in @entity1 (n = 909) with type 1 @entity6 enrolled in the @entity6 Control and Complications Trial/Epidemiology of @entity6 Interventions and Complications (DCCT/ EDIC). Univariate regression showed that @entity2002 levels were correlated with BMI (r = 0.15; P < 0.0001), HbA(1c) (r = 0.11; P = 0.0014), total @entity165 (r = 0.17; P < 0.0001), and LDL @entity165 (r = 0.16; P < 0.0001) in all @entity1 . In @entity1 , but not @entity1 , waist-to-hip ratio (r = 0.20; P < 0.0001) and @entity1674 (r = 0.13; P = 0.0047) also became powerful predictors of @entity2002 level; in @entity1 , but not @entity1 , @entity2002 was correlated with both diastolic (r = 0.16; P = 0.0011) and systolic (r = 0.11; P = 0.0241) blood pressure. @entity2002 was correlated with urinary albumin excretion rates in @entity1 (r = 0.13; P = 0.0033), but not in @entity1 . In both sexes, however, the development of @entity644 (albumin excretion >300 mg/24 h) was accompanied by 1.5-fold increment in plasma @entity2002 compared with @entity1 with normal excretion or microalbuminuria. In addition, high @entity2002 levels were associated with a lower average ankle-brachial index in @entity1 (r = -0.13; P = 0.0075), but not @entity1 . Multiple regression analyses demonstrated that plasma @entity2002 was independently correlated with high albumin excretion rate in @entity1 , and with low average ankle-brachial index in @entity1 . @entity2002 was not correlated with the severity of @entity989 . Carotid artery intima-medial thickness was not correlated with @entity2002 , and the G(-455)-->A polymorphism in the 5' promoter region of the beta- @entity2002 gene did not influence circulating @entity2002 levels. However, the presence of the more common G(-455) allele was associated with greater intima-medial thickness in the internal carotid artery (ANCOVA P = 0.045). Last, hyperfibrinogenemia in type 1 @entity6 is associated with components of the insulin resistance syndrome trait cluster, and the association is influenced by sex.

title: @entity2002 is a marker for nephropathy and peripheral vascular disease in type 1 @entity6 : studies of plasma @entity2002 and XXXX gene polymorphism in the DCCT/EDIC cohort.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity2002 :: ('2244', 'Gene') :: ['Fibrinogen', 'fibrinogen']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['macrovascular disease']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetes']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity2002 :: (2244,Gene) :: ['fibrinogen']


abstract: OBJECTIVE: We sought to assess the early success and safety of catheter-directed, ultrasound-assisted (CDUA) thrombolysis for @entity1151 ( @entity1151 ) in @entity1 deemed to be "high risk" for thrombolytic therapy. METHODS: A retrospective evaluation of @entity1 who underwent CDUA pulmonary thrombolysis in our practice during 39 months is reported. There were 91 @entity1 considered, all of whom presented with acute @entity1151 as diagnosed by computed tomography angiography. The ratio of the right ventricle to left ventricle diameter (RVaxial:LVaxial) was noted, as were preprocedure pulmonary artery pressures (PAPs). Demographic data, significant medical history, and procedure details were recorded. Standard thrombolysis protocol was followed (1 mg of tissue plasminogen activator per hour per catheter after an initial 2-mg bolus per catheter). Minitab 17 (Minitab Inc, State College, PA) was used for data analysis. RESULTS: There were 91 @entity1 who had a computed tomography diagnosis of acute @entity1151 and @entity120 (PAP >25 mm Hg). Seventeen @entity1 (19%) were deemed to be at high risk for @entity548 , predicted by recent @entity548 , major surgery within 3 weeks, acute @entity583 , and @entity1167 with cardiopulmonary resuscitation within 1 week. The high-risk @entity1 in our study were noted to have higher RV:LV ratios and lower @entity26 saturations on admission (P  < .05). On computed tomography angiography, the mean pretherapy RVaxial:LVaxial ratio was 1.5     0.4. The mean pretherapy PAP was 56.2     15.2 mm Hg. After 18.5     3.5 hours of thrombolysis, the mean post-therapy PAP was 34.3     10.4 mm Hg, with a pressure drop of 21.9     4.8 mm Hg (39% decrease; P  < .001). In total, seven @entity1 (8%) suffered @entity548 complications that required intervention-four @entity360 , a @entity1410 , and one gross @entity811 . Three of the seven complications occurred in the high-risk group (3/17) and the other four in the general population of @entity1 (4/74; P  = .118). Minor @entity548 complications (n  = 14 [15%]) did not require intervention and included puncture site @entity1410 , ecchymosis, and mild traumatic @entity811 . Considering all @entity548 complications, increasing RVaxial:LVaxial ratio was a predictor of any @entity548 complication, independent of all risk factors (P  = .005). CONCLUSIONS: CDUA thrombolysis for acute @entity1151 effectively reduced mean PAPs. Given the low incidence of major @entity548 complications, even in those deemed to be clinically at high risk for @entity548 , we additionally conclude that this procedure can be performed safely. Although larger studies with longer follow-up are necessary, CDUA pulmonary thrombolysis for the management of acute submassive @entity1151 appears to be effective in decreasing right-sided heart strain and can be performed with an acceptable risk profile.

title: Catheter-directed, ultrasound-assisted thrombolysis is a safe and effective treatment for @entity1151 , even in high-risk XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage', 'bleeding']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension']

entities_list: @entity1151 :: ('MESH:D011655', 'Disease') :: ['PE', 'acute pulmonary embolism']

entities_list: @entity1410 :: ('MESH:D006406', 'Disease') :: ['hematomas', 'rectus sheath hematoma']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity811 :: ('MESH:D006417', 'Disease') :: ['hematuria']

entities_list: @entity360 :: ('MESH:D006471', 'Disease') :: ['gastrointestinal bleeds']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: UNASSIGNED: Background Malaria treatment is recommended for @entity1 with suspected @entity2598 ( @entity2598 ) in West Africa, whether systeomatically or based on confirmed @entity311 diagnosis. At the Ebola treatment center in Foya, Lofa County, Liberia, the supply of @entity15280 - @entity15281 , a first-line antimalarial combination drug, ran out for a 12-day period in August 2014. During this time, @entity1 received the combination drug @entity506 - @entity16944 ; @entity16944 is a compound with anti-Ebola virus activity in vitro. No other obvious change in the care of @entity1 occurred during this period. Methods We fit unadjusted and adjusted regression models to standardized @entity1 -level data to estimate the risk ratio for @entity204 among @entity1 with confirmed @entity2598 who were prescribed @entity506 - @entity16944 ( @entity506 - @entity16944 group), as compared with those who were prescribed @entity15280 - @entity15281 ( @entity15280 - @entity15281 group) and those who were not prescribed any antimalarial drug (no-antimalarial group). Results Between June 5 and October 24, 2014, a total of 382 @entity1 with confirmed @entity2598 were admitted to the Ebola treatment center in Foya. At admission, 194 @entity1 were prescribed @entity15280 - @entity15281 and 71 were prescribed @entity506 - @entity16944 . The characteristics of the @entity1 in the @entity506 - @entity16944 group were similar to those in the @entity15280 - @entity15281 group and those in the no-antimalarial group. A total of 125 of the 194 @entity1 in the @entity15280 - @entity15281 group (64.4%) died, as compared with 36 of the 71 @entity1 in the @entity506 - @entity16944 group (50.7%). In adjusted analyses, the @entity506 - @entity16944 group had a 31% lower risk of @entity204 than the @entity15280 - @entity15281 group (risk ratio, 0.69; 95% confidence interval, 0.54 to 0.89), with a stronger effect observed among @entity1 without @entity311 . Conclusions @entity1 who were prescribed @entity506 - @entity16944 had a lower risk of @entity204 from @entity2598 than did @entity1 who were prescribed @entity15280 - @entity15281 . However, our analyses cannot exclude the possibility that @entity15280 - @entity15281 is associated with an increased risk of @entity204 or that the use of @entity506 - @entity16944 was associated with unmeasured @entity1 characteristics that directly altered the risk of @entity204 .

title: Effect of @entity506 - XXXX on Mortality Related to @entity2598 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity15281 :: ('MESH:C102070', 'Chemical') :: ['lumefantrine']

entities_list: @entity2598 :: ('MESH:D019142', 'Disease') :: ['Ebola virus disease', 'EVD']

entities_list: @entity16944 :: ('MESH:D000655', 'Chemical') :: ['amodiaquine']

entities_list: @entity15280 :: ('MESH:C032942', 'Chemical') :: ['artemether']

entities_list: @entity506 :: ('MESH:C039726', 'Chemical') :: ['artesunate']

answer: @entity16944 :: (MESH:D000655,Chemical) :: ['Amodiaquine']


abstract: PURPOSE: @entity4607 are lesions marked by a disorganized arrangement of mature neural elements and represent a rare cause of medically intractable @entity1625 . We present the clinical presentation and imaging findings of this rare entity. METHODS: History and neurophysiological studies of 14 @entity1 with pathologically confirmed @entity4607 who had surgery for intractable @entity1625 were reviewed. MRIs were available for review in 10 @entity1 . RESULTS: The lesions were most commonly located in the @entity1315 . @entity410 semiology was concordant with the anatomic location of the @entity4607 in all @entity1 . Nine of the thirteen @entity1 (69%) with the @entity4607 confined to one lobe had interictal spikes and sharp waves at the corresponding electrodes. The ictal pattern was confined to the same lobe of the @entity4607 in five of nine @entity1 with ictal recordings. Although imaging characteristics were variable, all @entity1 had signal increase on T2-weighted images and 50% of them had mild mass effect. Neocortical involvement was present in the majority of @entity1 (7/10), blurring of the gray/white matter interface was seen in seven @entity1 . Five of those seven @entity1 were found to have associated @entity6795 by pathology. CONCLUSION: @entity4607 represent a rare entity and may cause devastating @entity302 . Imaging characteristics are difficult to distinguish from those of some other developmental @entity5 . @entity4607 are frequently associated with microscopic @entity6795 ( @entity6795 ), thus underlining their malformative etiology.

title: @entity4607 and XXXX : clinical and imaging characteristics.

entities_list: @entity1625 :: ('MESH:D004828', 'Disease') :: ['focal epilepsy']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity6795 :: ('MESH:D054220', 'Disease') :: ['CD', 'cortical dysplasia']

entities_list: @entity1315 :: ('MESH:D004833', 'Disease') :: ['temporal and frontal lobes']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity4607 :: ('MESH:D006222', 'Disease') :: ['hamartomas', 'hamartoma', 'Hamartomas', 'Cerebral hamartomas']

answer: @entity302 :: (MESH:D004827,Disease) :: ['epilepsy']


abstract: BACKGROUND: Antibiotic resistance typically confers a biological fitness cost on bacteria that can be manifested as a decreased growth rate in culture media and experimental animals. However, there are limited experimental data on the relative fitness of resistant and susceptible bacteria during growth in their natural environment. OBJECTIVE: We have developed a @entity1 competition model to investigate the relative fitness of antibiotic-resistant and -susceptible bacteria. MATERIALS AND METHODS: A non-epidemic @entity5938 was isolated from skin, and a @entity1215 -resistant (RifR) clone was selected. The RifR marker was used to distinguish the inoculated strains from the resident population of coagulase-negative staphylococci. The RifR strains were further selected for resistance to @entity2177 (CipR) and @entity12119 (FusR). A 1:1 mix of susceptible and resistant bacteria was applied on the forearms of 12 volunteers. Competition was monitored by sampling bacteria from skin and determining their relative numbers. RESULTS: Resistance to @entity2177 due to @entity30939 mutations did not decrease the growth rate in vitro, and the CipR/CipS ratio was close to 1 during day 1 and 3 in the in vivo competition experiments. In contrast, @entity12119 resistance due to fusA mutations resulted in a decrease in the growth rate in vitro and a considerable loss of fitness in the competition. The FusR/FusS ratio diminished from 1.3 to 0.023 in 3 days. CONCLUSIONS: These data show that @entity1 volunteers can be used as a simple and relevant model to study the biological cost of resistance.

title: Fitness of antibiotic resistant XXXX assessed by competition on the skin of @entity1 volunteers.

entities_list: @entity12119 :: ('MESH:D005672', 'Chemical') :: ['fusidic acid']

entities_list: @entity5938 :: ('1282', 'Species') :: ['Staphylococcus epidermidis strain']

entities_list: @entity2177 :: ('MESH:D002939', 'Chemical') :: ['ciprofloxacin']

entities_list: @entity1215 :: ('MESH:D012293', 'Chemical') :: ['rifampicin']

answer: @entity5938 :: (1282,Species) :: ['Staphylococcus epidermidis']


abstract: OBJECTIVE: To compare the relative effectiveness of the Polysymptomatic Distress Scale (PSD) with the Symptom Impact Questionnaire (SIQR), the disease-neutral revision of the updated @entity239 Impact Questionnaire (FIQR), in their ability to assess disease activity in @entity1 with @entity627 both with and without @entity239 ( @entity239 ). METHODS: The study included 321 @entity1 from 8 clinical practices with some 16 different @entity1118 . Disease severity was assessed by the Medical Outcomes Study Short Form-36 (SF-36). Univariate analyses were used to assess the magnitude of PSD and SIQR correlations with SF-36 subscales. Hierarchical stepwise regression was used to evaluate the unique contribution of the PSD and SIQR to the SF-36. Random forest regression probed the relative importance of the SIQR and PSD components as predictors of SF-36. RESULTS: The correlations with the SF-36 subscales were significantly higher for the SIQR (0.48 to 0.78) than the PSD (0.29 to 0.56; p < 0.001). Stepwise regression revealed that the SIQR was contributing additional unique variance on SF-36 subscales, which was not the case for the PSD. Random forest regression showed SIQR Function, Symptoms, and Global Impact subscales were more important predictors of SF-36 than the PSD. The single SIQR @entity158 item contributed 55% of SF-36 @entity158 variance compared to 23% with the 19-point WPI (the @entity158 ). CONCLUSION: The SIQR, the disease-neutral revision of the updated FIQ, has several important advantages over the PSD in the evaluation of disease severity in @entity1118 .

title: Evaluating Disease Severity in @entity1118 @entity1 with and without XXXX : A Comparison of the Symptom Impact Questionnaire and the Polysymptomatic Distress Scale.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity239 :: ('MESH:D005356', 'Disease') :: ['Fibromyalgia', 'fibromyalgia', 'FM']

entities_list: @entity627 :: ('MESH:D012216', 'Disease') :: ['rheumatic disorders']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'Widespread Pain Index component of PSD']

entities_list: @entity1118 :: ('MESH:D059350', 'Disease') :: ['chronic pain disorders']

answer: @entity239 :: (MESH:D005356,Disease) :: ['Fibromyalgia']


abstract: BACKGROUND: Overweight and @entity28 decrease the effectiveness of antihypertensive therapy despite the more frequent use of polytherapy. One method for improving therapy effectiveness is by decreasing non-compliance with the use of @entity2300 ( @entity2300 ). The aim of this study was to assess the effectiveness, tolerance, and satisfaction with @entity3372 / @entity3591 @entity2300 antihypertensive therapy in relation to nutritional status. METHODS: The survey enrolled 24,240 @entity101 @entity1 recently switched to @entity3372 / @entity3591 @entity2300 (EGIRAMLON) at the same doses as previously prescribed separate pills. RESULTS: The effectiveness of antihypertensive therapy increased during follow-up from 32.9% to 76.5%. Overweight and @entity28 were associated with the increased risk of not attaining the recommended BP values [adjusted for age OR=0.74 (95% CI 0.67-0.83) and 0.70 (0.61-0.81) for overweight; 0.54 (0.47-0.60) and 0.49 (0.42-0.57) for @entity28 , at the first and the second examination, respectively]. "Very good" or "good" the FDP tolerance was reported by 98.8%, 97.6% and 96.4%, respectively. Adverse events (AE) were reported in 0.35% of @entity1 regardless of nutritional status. High levels of satisfaction with the @entity2300 were reported by 57.0% of @entity1 with normal weight, 54.5% of overweight, and 50.6% with @entity28 . Effectiveness and convenience were the most important for @entity1 . CONCLUSIONS: The effectiveness of therapy with @entity3372 / @entity3591 @entity2300 in the study population was high, but slightly lower in overweigh and @entity28 . This @entity2300 was well tolerated and a significant number of @entity1 satisfied with the therapy regardless of nutritional status. Although the perceived tolerance and satisfaction with treatment were lower in @entity28 and overweight than in normal weight @entity1 ; the incidence of AE and perceived benefit from the use of a single-pill, compared to multiple tablets, were comparable irrespective of nutritional status.

title: @entity3372 / XXXX single pill - Effectiveness, tolerance and @entity1 satisfaction with antihypertensive therapy in relation to nutritional status.

entities_list: @entity3372 :: ('MESH:D017257', 'Chemical') :: ['ramipril']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity']

entities_list: @entity3591 :: ('MESH:D017311', 'Chemical') :: ['amlodipine']

entities_list: @entity2300 :: ('MESH:D011681', 'Disease') :: ['FDC', 'fixed-dose combinations']

answer: @entity3591 :: (MESH:D017311,Chemical) :: ['amlodipine']


abstract: @entity1 with @entity2175 have a twofold to fourfold increased risk of dying from the complications of @entity65 . @entity731 and vascular @entity715 are major contributors. The increased risk is present before fasting @entity4854 is seen. These individuals often have a sedentary life-style, poor physical conditioning, @entity2690 resistance, @entity28 , @entity101 , @entity2299 , and a prothrombotic state. @entity4854 is then added to these risk markers. Microalbuminuria may precede @entity4854 in @entity2175 , occurs in 30% to 40% of these individuals after @entity6 is established, and is a predictor of cardiovascular events. Early intervention in high-risk individuals may delay or prevent fasting @entity4854 . An all-inclusive approach that focuses on early risk factor (or marker) identification and management to prevent or delay accelerated @entity731 and @entity715 in @entity2175 is an attractive strategy. However, the database to support this strategy is limited. In particular, large-scale prospective trial data are not available to support the concept of intensive glycemic regulation to prevent progression of @entity66 in @entity2175 . This is in contrast to the situation regarding microvascular disease of the eyes and kidneys. Recently, indirect data of a correlative nature have emerged, and short- and long-term prospective trials at early and late stages of @entity2175 are now being reported. These studies are analyzed and interpreted in this report. In contrast, the database to support an intensive antiplatelet regimen to prevent vascular @entity715 events in @entity1 with @entity2175 is large, and these studies are reviewed. They are of a type and magnitude to allow definite recommendations for aspirin therapy in @entity2175 . Aggressive therapy directed at @entity101 , @entity407 , and elevated urinary albumin in @entity1 with @entity2175 appears to be indicated. Increased attention to the multifactorial aspects of treatment of the type II @entity6 @entity1 is needed. Our present challenge is to translate these findings for @entity1 and primary health care providers so that effective actions may be implemented.

title: Multifactorial aspects of the treatment of the type II XXXX @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'patients', 'people', 'People']

entities_list: @entity2175 :: ('MESH:D003924', 'Disease') :: ['type II diabetes']

entities_list: @entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipidemia']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['centripetal obesity']

entities_list: @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes', 'diabetic']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['macrovascular disease']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis', 'Atherosclerosis']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia', 'Chronic hyperglycemia']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'thrombotic']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetic']


abstract: @entity1 with @entity3052 were given repeated cycles consisting of infusions of @entity1499 followed by "rescue" with @entity4181 . Peripheral blood leukemic cells were harvested from @entity1 before cyclical treatment, and the rates of incorporation of @entity1014 and of @entity14322 into @entity3141 (DNA) were measuared in vitro. There was no relationship between the pretreatment incorporation of either @entity37131 into DNA and the clinical response to therapy. @entity1499 suppressed @entity14322 incorporation into DNA by the leukemic blasts in vitro, but the @entity1 whose cells were most sensitive to this effect did not necessarily go into remission when treated. Leukemic cells were sampled during @entity1499 infusions and the @entity37131 incorporation rates were determined. @entity1014 incorporation into DNA was variably affected. If, by the end of the first infusion, it remained elevated, remission rarely followed, whereas if it was below the pretreatment value, remission was much more likely. In all cases, @entity14322 incorporation was suppressed during the infusion. The greatest suppression occurred in @entity1 who went on to remission, but the suppression did not correlate with that expected from pretreatment in vitro tests unless due weight was given to the concomitant effects of the @entity1499 therapy on @entity1014 incorporation. Leukemic blasts surviving successive cycles of therapy became progressively more resistant to the suppressing effects of @entity1499 in vitro. This resistance became especially marked in the blasts of @entity1 who did not go into remission. During @entity1499 infusions, inhibition of leukemic cell @entity9796 reductase activity was greatest in blasts of @entity1 whose disease subsequently remitted.

title: Treatment of leukemia with large doses of @entity1499 and XXXX : clinical-biochemical correlates.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity4181 :: ('MESH:D002955', 'Chemical') :: ['folinic acid']

entities_list: @entity3141 :: ('CHEBI:16991', 'Chemical') :: ['deoxyribonucleic acid']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute leukemia']

entities_list: @entity37131 :: ('CHEBI:18274', 'Chemical') :: ['deoxynucleoside']

entities_list: @entity14322 :: ('MESH:D003857', 'Chemical') :: ['deoxyuridine']

entities_list: @entity1014 :: ('MESH:D013936', 'Chemical') :: ['thymidine', 'Thymidine']

entities_list: @entity9796 :: ('MESH:C010920', 'Chemical') :: ['dihydrofolate']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['Methotrexate', 'methotrexate']

answer: @entity4181 :: (MESH:D002955,Chemical) :: ['folinic acid']


abstract: BACKGROUND: Very little is known about the pharmacokinetics of chemotherapeutic agents in @entity1 also being treated with continuous ambulatory peritoneal dialysis. We sought to evaluate the pharmacokinetics of @entity900 and @entity1487 in plasma and peritoneal dialysate in a @entity1 being treated for @entity420 . METHODS: A single @entity1 with @entity420 and on peritoneal dialysis for @entity454 was treated with @entity900 25  mg/m(2) on day 1 of weeks 1 and 5 and continuous infusional @entity1487 1000  mg/m(2)/day on days 1-4 of weeks 1 and 5 along with daily radiation therapy. Intense plasma and dialysate sampling was performed during the week 5 administration, followed by quantitation of @entity902 by atomic absorption spectrophotometry and @entity1487 by LC-MS/MS. RESULTS: Following systemic administration, clearance of ultrafilterable (active) @entity902 over the first 6  h was 20.8  L/h, which is lower than previously reported clearance levels of ultrafilterable @entity902 . Total @entity902 AUC was 131   g  h/mL, also higher than an AUC previously reported for total @entity902 in @entity1 with normal renal function. @entity902 -related material was detected in the peritoneal cavity, but this is likely inactive. @entity1487 penetrated the intraperitoneal cavity, but the contribution of peritoneal dialysis to drug clearance was negligible at 0.072  %. CONCLUSIONS: Administration of intravenous @entity900 and @entity1487 chemotherapy to a @entity1 treated with continuous ambulatory peritoneal dialysis is feasible, but clearance in dialysate is nominal, thus suggesting that dose reduction is indicated for @entity900 . Systemic drug administration results in limited intraperitoneal penetration of @entity1487 and inactive @entity902 species.

title: A pharmacokinetic analysis of XXXX and @entity1487 in a @entity1 with esophageal cancer on peritoneal dialysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity902 :: ('MESH:D010984', 'Chemical') :: ['Platinum', 'platinum']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['esophageal adenocarcinoma']

entities_list: @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-Fluorouracil', '5-fluorouracil']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease']

answer: @entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']


abstract: OBJECTIVE: To describe methods, recruitment success, and 1-y results of a study evaluating the effectiveness of phone- and mail-based weight-loss interventions in a managed care setting. DESIGN: Randomized clinical trial with three groups, that is, usual care, mail intervention, and phone intervention. SUBJECTS: In total, 1801 overweight members of a managed-care organization (MCO). MEASUREMENTS: Height, weight, medical status, and weight-loss history were measured at baseline. Participation in intervention activities was monitored for 12 months in the two active treatment groups. Self-reported weight was obtained at 6 and 12 months. RESULTS: More individuals assigned to mail treatment started it (88%) than did those assigned to phone treatment (69%). However, program completion rates were higher in the phone (36%) than mail (7%) intervention. The mean weight losses were 1.93, 2.38, and 1.47 kg at 6 months in the mail, phone, and usual care groups, respectively. The differences between the phone and usual care groups were statistically significant. The mean weight losses at 12 months did not differ by treatment group (2.28 kg mail, 2.29 kg phone, and 1.92 kg usual care). Greater @entity353 was seen in @entity1 , older @entity1 , and those with no prior experience in a weight-loss program. Heavier @entity1 and those who reported current treatment for @entity308 lost less weight. CONCLUSION: Although mail- and phone-based weight-loss programs can be delivered to large numbers of @entity1 in an MCO setting, additional work is needed to enhance their clinical efficacy as well as to assess their costs.

title: Mail and phone interventions for XXXX in a managed-care setting: Weigh-To-Be one-year outcomes.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'people', 'men']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss']

answer: @entity353 :: (MESH:D015431,Disease) :: ['weight loss']


abstract: BACKGROUND: Only a minority of @entity1 with @entity1030 ( @entity1030 ) have access to pulmonary rehabilitation (PR). Home-based solutions such as telehealthcare, have been used in efforts to make PR more available. The aim of this systematic review was to investigate the effects of telehealthcare on physical activity level, physical capacity and @entity1353 in @entity1 with @entity1030 , and to describe the interventions used. METHODS: Randomized controlled trials were identified through database searches, reference lists and included authors. Articles were reviewed based on eligibility criteria by three authors. Risk of bias was assessed by two authors. Standardized mean differences (SMD) or mean differences (MD) with 95% CI were calculated. Forest plots were used to present data visually. RESULTS: Nine studies (982 @entity1 ) were included. For physical activity level, there was a significant effect favoring telehealthcare (MD, 64.7  min; 95% CI, 54.4-74.9). No difference between groups was found for physical capacity (MD, -1.3  m; 95% CI, -8.1-5.5) and @entity1353 (SMD, 0.088; 95% CI, -0.056-0.233). Telehealthcare was promoted through phone calls, websites or mobile phones, often combined with education and/or exercise training. Comparators were ordinary care, exercise training and/or education. CONCLUSIONS: The use of telehealthcare may lead to improvements in physical activity level, although the results should be interpreted with caution given the heterogeneity in studies. This is an important area of research and further studies of the effect of telehealthcare for @entity1 with @entity1030 would be beneficial. REGISTRATION: In PROSPERO 2012: CRD42012003294. Study protocol: http://www.crd.york.ac.uk/PROSPEROFILES/3294_PROTOCOL_20121016.pdf.

title: Telehealthcare in XXXX : A systematic review and meta-analysis on physical outcomes and @entity1353 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic obstructive pulmonary disease', 'COPD']

answer: @entity1030 :: (MESH:D029424,Disease) :: ['COPD']


abstract: @entity1160 ( @entity7647 ) has been shown to attenuate cytokine release from LPS-stimulated @entity1 peripheral blood mononuclear cells; however, the in vivo antiinflammatory effect of @entity7647 in polymicrobial sepsis and @entity649 is unknown. This study evaluates the effect of @entity7647 on inflammatory cytokine release and the pathways that may mediate antiinflammatory effects of @entity7647 in the lung. Either 0.75 g/kg of @entity7647 or saline placebo (SP) was administered to male @entity35 1 h after cecal ligation and puncture (CLP). NF-kappaB activation, IKBalpha degradation, phosphorylation of @entity1435 MAPK, @entity3963 , and @entity14520 expression were evaluated in lung tissue 6 h post-CLP. Lung tissue iNOS and @entity9554 , @entity310 , @entity650 , and @entity8923 cytokines were assayed. Last, lung histopathology for occurrence of @entity649 and survival were examined. @entity7647 given 1 h postsepsis led to inhibition of lung tissue NF-kappaB activation (P < 0.001 vs. SP), attenuated degradation of IKBalpha, and inhibited phosphorylation of @entity1435 MAPK, and @entity3963 , pathways critical for cytokine release. @entity7647 treatment increased @entity14520 peptide expression and significantly attenuated @entity310 and @entity650 6 h after CLP. @entity8923 was attenuated by @entity7647 at multiple time points post-CLP. Further, @entity7647 abrogated increases in lung iNOS expression and enhanced lung @entity9554 postsepsis. Finally, @entity7647 prevented the histopathologic appearance of @entity649 after sepsis and significantly improved survival. These data reveal that @entity7647 exerts an antiinflammatory effect in sepsis that may be mediated via attenuation of multiple pathways of inflammation such as NF-kappaB, @entity1435 MAPK, @entity3963 , and @entity14520 . @entity7647 also showed an inhibition of increases in iNOS expression. The antiinflammatory effect of @entity7647 was associated with attenuation of @entity649 and mortality.

title: GLUTAMINE PREVENTS ACTIVATION OF NF-kappaB AND STRESS KINASE PATHWAYS, ATTENUATES INFLAMMATORY CYTOKINE RELEASE, AND PREVENTS XXXX ( @entity649 ) FOLLOWING SEPSIS.

entities_list: @entity1160 :: ('CHEBI:28300', 'Chemical') :: ['Glutamine']

answer: @entity649 :: (MESH:D012128,Disease) :: ['ACUTE RESPIRATORY DISTRESS SYNDROME']


abstract: OBJECTIVE: @entity543 is a common manifestation of systemic @entity731 . Apart from traditional risk factors, genetic determinants, such as polymorphisms of the @entity916 angiotensin system (RAS), may be relevant in modulating the @entity731 process leading to @entity543 . In this study, we investigated the role of @entity1289 ( @entity1289 ) I/D and @entity26699 , @entity2178 ( @entity2178 ) @entity7742 , and angiotensin type 1 receptor ( @entity7743 ) @entity7744 polymorphisms in modulating the susceptibility to the disease. METHODS: Eight hundred twenty-one consecutive @entity1 with severe @entity543 (>= 70%) and 847 control subjects were investigated. RESULTS: A significant difference in genotype distribution (P < .0001) and allele frequency (P < .0001) between @entity1 and controls for the @entity1289 I/D polymorphism, but not for the other single-nucleotide polymorphisms investigated, was observed. The @entity1289 D allele frequency was significantly higher in @entity1 without traditional risk factors in comparison with that observed in those with at least one risk factor (0.71 vs 0.61; P = .04). The @entity1289 D allele significantly influenced @entity543 under dominant, recessive, and additive model of inheritance at both univariate (P < .0001) and multivariate analysis (P < .0001). When the combined effect of RAS unfavorable alleles was considered, @entity1 carrying less than three alleles had a lower risk of @entity543 (odds ratio [OR], 0.79 [0.63-0.99]; P = .05), while carriers of more than four unfavorable alleles had an increased risk (OR, 1.44 [1.12-1.84]; P = .004), in comparison with subjects carrying three or four unfavorable alleles. @entity1289 D allele frequency was similar in @entity1 with and without additional @entity731 localizations (0.61 vs 0.62, respectively). CONCLUSIONS: Our findings evidence a role for @entity1289 I/D polymorphism in influencing the susceptibility to @entity543 , even in the absence of traditional risk factors. Interestingly, our findings provided further information concerning the role of this polymorphism in modulating the @entity731 process apart from its different localizations.

title: Association between polymorphisms of the @entity916 angiotensin system and XXXX .

entities_list: @entity1289 :: ('1636', 'Gene') :: ['ACE', 'angiotensin-converting enzyme']

entities_list: @entity2178 :: ('183', 'Gene') :: ['AGT', 'angiotensinogen']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic', 'atherosclerosis']

entities_list: @entity543 :: ('MESH:D016893', 'Disease') :: ['carotid stenosis', 'Carotid stenosis']

answer: @entity543 :: (MESH:D016893,Disease) :: ['carotid stenosis']


abstract: OBJECTIVE: To describe the diagnostic yield and prognosis for @entity1 with @entity132 . BACKGROUND: The aetiology, utility of diagnostic procedures, and outcome of @entity132 in @entity1 with @entity12371 having only subjective @entity3002 on examination is unknown. METHODS: @entity1 were prospectively identified with @entity132 in a tertiary care institution from 1998-2002. Diagnostic procedures were analysed for sensitivity and clinical follow up was performed. RESULTS: Thirty four @entity1 , 25 (74%) @entity1 , of age 35 (SD 11) years were identified. The @entity132 occurred on the left side in 23 (68%) cases. Neuroimaging of the brain demonstrated @entity854 representing ischaemic aetiology in one case. Other diagnostic testing including cerebrospinal fluid examination, electrophysiological testing, carotid ultrasonography, echocardiography, and blood testing revealed no @entity854 . Sixteen @entity1 (47%) continued to complain of hemisensory difficulties after all investigations were completed at 9.6 (5.8) days. One @entity1 with a history of @entity1252 and positive antiphospholipid antibodies had a second event diagnosed as @entity64 seven months after presentation. Clinical follow up at 16 (7) months revealed persisting symptoms in 6 (20%) of 30 @entity1 . Six (50%) of 12 @entity1 agreeing to psychiatric assessment received diagnoses of @entity1316 . CONCLUSIONS: Diagnostic yield in @entity132 is low, and prognosis is almost always uniformly benign. The author advocates careful assessment of medical history and consideration for neuroimaging in this group of @entity1 .

title: XXXX is associated with a low diagnostic yield and a nearly uniform benign prognosis.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'patient']

entities_list: @entity12371 :: ('MESH:C580202', 'Disease') :: ['exclusive hemibody complaints']

entities_list: @entity132 :: ('MESH:D010468', 'Disease') :: ['hemisensory syndrome']

entities_list: @entity3002 :: ('MESH:D009421', 'Disease') :: ['sensory abnormalities']

entities_list: @entity1252 :: ('MESH:D008180', 'Disease') :: ['systemic lupus erythematosus']

entities_list: @entity1316 :: ('MESH:D019964', 'Disease') :: ['personality or mood disorders']

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['diagnostic abnormalities']

answer: @entity132 :: (MESH:D010468,Disease) :: ['Hemisensory syndrome']


abstract: The extensive use of invasive procedures and of long-term @entity4258 prophylaxis in the management of cirrhotic @entity1 may have influenced the epidemiology of @entity2348 in @entity82 . We conducted a prospective evaluation of all @entity2348 diagnosed in @entity1 with @entity82 in a Liver Unit between April 1998 and April 2000. A total of 405 @entity1 presented 572 @entity2348 in 507 admissions. @entity298 was the most frequent @entity281 (138 cases). Gram-positive cocci were responsible for 53% of total @entity2348 in the study, being the main bacteria isolated in @entity580 (59%). @entity1 requiring treatment in an intensive care unit and those submitted to invasive procedures presented a higher rate of @entity281 caused by gram-positive cocci (77% vs. 48%, P <.001 and 58% vs. 40%, P <.02, respectively). Fifty percent of culture-positive spontaneous @entity298 in @entity1 on long-term @entity4258 administration (n = 93) and 16% in @entity1 not receiving this therapy (n = 414) were caused by @entity1536 -resistant gram-negative bacilli, P =.01. The rate of culture-positive spontaneous @entity298 caused by @entity206 - @entity207 -resistant gram-negative bacilli was also very high in @entity1 on long-term @entity4258 administration (44% vs. 18%, P =.09). In conclusion, @entity281 caused by gram-positive cocci have markedly increased in @entity82 . This phenomenon may be related to the current high degree of instrumentation of cirrhotic @entity1 . @entity1536 -resistant spontaneous @entity298 constitutes an emergent problem in @entity1 on long-term @entity4258 prophylaxis, with @entity799 not being a valid alternative.

title: @entity2348 in @entity82 : epidemiological changes with invasive procedures and XXXX prophylaxis.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis']

entities_list: @entity4258 :: ('MESH:D009643', 'Chemical') :: ['norfloxacin']

entities_list: @entity799 :: ('MESH:D015662', 'Chemical') :: ['trimethoprim-sulfamethoxazole']

entities_list: @entity2348 :: ('MESH:D001424', 'Disease') :: ['bacterial infections']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'infections']

entities_list: @entity580 :: ('MESH:D003428', 'Disease') :: ['nosocomial infections']

entities_list: @entity207 :: ('MESH:D013420', 'Chemical') :: ['sulfamethoxazole']

entities_list: @entity298 :: ('MESH:D010538', 'Disease') :: ['bacterial peritonitis', 'Spontaneous bacterial peritonitis']

entities_list: @entity206 :: ('MESH:D014295', 'Chemical') :: ['trimethoprim']

entities_list: @entity1536 :: ('CHEBI:23765', 'Chemical') :: ['Quinolone', 'quinolone']

answer: @entity4258 :: (MESH:D009643,Chemical) :: ['norfloxacin']


abstract: OBJECTIVE: To determine the incidence of @entity4838 in workers following @entity542 in the work place, to define its relationship to the site, severity of injury and direction of force. The demographics of head injured workers were also assessed to determine if those with olfactory loss were more likely to have sustained a @entity130 . METHODS: 3438 consecutive @entity1 referred from the Workplace Safety and Insurance Board (WSIB) in the province of Ontario who sustained a work related @entity542 were assessed between 1987-2014 for olfactory and @entity409 at a tertiary referral university hospital. RESULTS: @entity4838 ( @entity4838 ) was identified in 413 of 3438 @entity1 (12.0%) of which 321 were diagnosed with @entity4838 and 92 with @entity9905 . In our series, injuries from a fall were the commonest cause for @entity4838 and a frontal or mid-face impact was more likely to result in @entity4838 than other regions [p=0.0002]. A @entity909 ( @entity909 ) of any duration correlated with @entity4838 . In those with @entity4838 , an associated skull @entity174 occurred in 37.1% of @entity1 and a CSF leak in 4.1%, which was significantly higher compared, to those without @entity4838 (<0.0001). @entity1 with @entity4838 had a higher incidence of cochlear and vestibular loss (19.9% and 20.6% respectively) compared to those without @entity4838 (14.3% and 17.1% respectively). CONCLUSIONS: Post traumatic @entity4838 is more likely to occur in @entity1 who experienced a moderate to severe @entity542 , @entity909 and more likely to result from a frontal or mid-face blow to the skull. @entity409 is likely to occur concurrently with @entity4838 . This article is protected by copyright. All rights reserved.

title: Olfactory and XXXX after @entity542 in the workplace: an updated series.

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture']

entities_list: @entity542 :: ('MESH:D006259', 'Disease') :: ['head injury']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['Cochleovestibular dysfunction', 'cochleovestibular dysfunction']

entities_list: @entity909 :: ('MESH:D014474', 'Disease') :: ['loss of consciousness', 'LOC']

entities_list: @entity4838 :: ('MESH:D000857', 'Disease') :: ['OD', 'olfactory dysfunction', 'Olfactory dysfunction', 'anosmia']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['cochleovestibular injury']

answer: @entity409 :: (MESH:D008107,Disease) :: ['Cochleovestibular dysfunction']


abstract: AIM: To determine the activity of @entity224 dismutase, @entity7525 and the concentration of @entity1234 ( @entity1865 ) in @entity7462 , lens and red blood cells after application of @entity9809 ( @entity13102 ) into vitreous of @entity95 . MATERIAL AND METHODS: 0.5 ml of 100% SF6 was injected into the vitreous of 24 @entity95 of New Zealand race. The animals were randomly divided into 3 groups (of 8 @entity95 each) depending on the observation day: group 1-2nd day of experiment, group 2-7th day and group 3-14th observation day. The control group (gr. 0) consisted of 6 @entity95 that did not undergo any operations. Activity of @entity224 dismutase, @entity7525 and @entity1865 concentration were determined in @entity1503 . RESULTS: On the 7th day of observation an increased activity of dismutase and @entity7525 as well as simultaneous increased @entity1865 concentration were observed. In the lens on the 7th day the increased activity of dismutase was significant in relation to the results in the next time interval, whereas @entity1865 concentration was significantly lower in all time intervals of the experiment in comparison with control group. In erythrocytes an increased activity of @entity7525 was noticed on the 2nd and 14th day. CONCLUSIONS: Increased occurrence of active @entity26 species in @entity7462 leads to insufficiency of the antioxidant system and intensification of peroxidation processes, which is reflected by increased @entity1865 concentration. However, in the lens of this experimental model a slight stimulation of antioxidant system by a small number of free radicals is observed, which provokes a reaction of sweeping them away. Efficiency of lens antioxidant system is secured by weakening of peroxidation processes, which is expressed in minimal drop of @entity1865 concentration.

title: [Changes in the antioxidant system of the @entity7462 , lens and erythrocytes after @entity9809 application to the vitreous of XXXX ].

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity9809 :: ('MESH:D013459', 'Chemical') :: ['sulfur hexafluoride']

entities_list: @entity7462 :: ('MESH:C562390', 'Disease') :: ['aqueous humor']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['aqueous humor, lens and systemic blood erythrocytes']

entities_list: @entity1234 :: ('MESH:D008315', 'Chemical') :: ['malondialdehyde']

entities_list: @entity224 :: ('MESH:D013481', 'Chemical') :: ['superoxide']

answer: @entity95 :: (9986,Species) :: ['rabbits']


abstract: BACKGROUND/PURPOSE: The purpose of this systematic review is to update the available data for complications following orthognathic surgery in @entity3384 @entity1 . METHODS: Three electronic databases (Medline, Embase, and Cochrane) were searched for publications from 1990 to 2014. RESULTS: A total of 26 articles were selected including 1003 @entity1 (male: 391, female: 353, 259: not mentioned) who underwent @entity3573 for @entity3384 . Mean age at surgery was 19.3 years (range: 8.5-60 years). Overall perioperative complications were reported in 126 cases (12.76%). The most common complication was closure failure of pre-existing palatal @entity292 (28.57%), followed by @entity73 (16.79%), closure failure of pre-existing @entity292 (10.74%), @entity1464 (4.55%), and @entity177 stabilization in bilateral cases (4.55%). Severe @entity455 included one @entity2548 (0.10%), one maxillary @entity439 (0.10%), and one cavernous sinus @entity715 (0.10%). Mean horizontal relapse rate was 17.9% (range: -20.0% to 37.2%), and mean vertical relapse rate was 35.4% (range: -25.9% to 162.5%). Reoperation rate was 12.2% (range: 0.0-64.0%). Prospective studies or randomized trials were rare. CONCLUSION: To obtain a dataset with higher evidence, a prospective multicenter study should be conducted with clearly defined criteria for each complication.

title: Complications following orthognathic surgery for @entity1 with XXXX : A  systematic review.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1464 :: ('MESH:D005889', 'Disease') :: ['gingival recession']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular complications']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['velopharyngeal impairment']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['failure of premaxilla']

entities_list: @entity292 :: ('MESH:D005402', 'Disease') :: ['fistula', 'alveolar fistula']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysm']

entities_list: @entity3573 :: ('MESH:D008439', 'Disease') :: ['maxillary osteotomies']

entities_list: @entity2548 :: ('MESH:D001164', 'Disease') :: ['arteriovenous fistula']

entities_list: @entity3384 :: ('MESH:D002971', 'Disease') :: ['cleft lip/palate', 'cleft lip and/or palate']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

answer: @entity3384 :: (MESH:D002971,Disease) :: ['cleft lip/palate']